Clinical trial
Study Evaluating GAP-486 in Heart Rhythm
NCT00137293 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00137293 |
|---|---|
| Title | Study Evaluating GAP-486 in Heart Rhythm |
| Official title | A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486 |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arrhythmia |
| Intervention type | Drug |
| Interventions | GAP-486 (ZP-123), 0.9% Sodium Chloride, USP |
| Enrollment | 30 |
| Start date | Nov 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Aug 29, 2005 |
| Last update posted | Dec 10, 2007 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: